Page 4,670«..1020..4,6694,6704,6714,672..4,6804,690..»

What is a Mild Traumatic Brain Injury (mTBI)? – Video

Posted: Published on January 24th, 2014

What is a Mild Traumatic Brain Injury (mTBI)? http://www.injurylawyercanada.com/blog/what-is-a-mild-traumatic-brain-injury/ 70-90% of brain injuries are considered "mild". It is important to realize, how... By: Roger R. Foisy … Continue reading →

Posted in Brain Injury Treatment | Comments Off on What is a Mild Traumatic Brain Injury (mTBI)? – Video

NFL Brain Injury Settlement put on Hold: San Diego Attorneys of Mitchell & Shea Support Judge’s Decision

Posted: Published on January 24th, 2014

San Diego, CA (PRWEB) January 23, 2014 As a highly successful personal injury law firm in California that has represented many injured NFL players, Mitchell & Shea has been focused on the latest developments in the $765 million dollar settlement between the NFL and more than 4,500 former NFL players. The players sued the league over issues related to concussions and brain injuries. They argued that they were not informed or protected effectively enough while playing in the NFL. The settlement was announced in August. The judge presiding over the settlement, Anita B. Brody of the United States District Court for the Eastern District of Pennsylvania, recently put the settlement on hold until more specific details are disclosed. Patrick Shea of Mitchell & Shea says "the NFL seems to have made a good faith effort to provide for these players and to invest in making safety a higher priority. However, Judge Brody has identified some significant problems with the settlement. The settlement should provide fair compensation to players, provide for extensive research into head injury issues and support education efforts. $765 million may sound like a lot of money but, realistically, it may not accomplish what is necessary." Several players … Continue reading →

Posted in Brain Injury Treatment | Comments Off on NFL Brain Injury Settlement put on Hold: San Diego Attorneys of Mitchell & Shea Support Judge’s Decision

Teva and Active Biotech Remain Committed to the Develop.

Posted: Published on January 24th, 2014

Active Biotech Remain Committed to the Development of NERVENTRA (laquinimod) for Multiple Sclerosis Following the Negative Opinion from the EMA's CHMP JERUSALEM, Israel & LUND, Sweden, January 24, 2014 - Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The CHMP has concluded that the risk-benefit profile of NERVENTRA is not favorable at this time. In accordance with European regulations, Teva and Active Biotech intend to request a re-examination of the CHMP opinion. Teva and Active Biotech are focusing on evaluating the CHMP's review and will continue to liaise closely with the EMA in working to make NERVENTRA available as a new treatment option for patients with RRMS in Europe. ABOUT NERVENTRA NERVENTRA is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed for the treatment of relapsing-remitting MS (RRMS) and progressive MS (PMS). In extensive non-clinical and clinical studies NERVENTRA has … Continue reading →

Posted in MS Treatment | Comments Off on Teva and Active Biotech Remain Committed to the Develop.

Teva and Active Biotech Remain Committed to the Development of NERVENTRA® (laquinimod) for Multiple Sclerosis …

Posted: Published on January 24th, 2014

JERUSALEM & LUND, Sweden--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). The CHMP has concluded that the risk-benefit profile of NERVENTRA is not favorable at this time. In accordance with European regulations, Teva and Active Biotech intend to request a re-examination of the CHMP opinion. Teva and Active Biotech are focusing on evaluating the CHMPs review and will continue to liaise closely with the EMA in working to make NERVENTRA available as a new treatment option for patients with RRMS in Europe. ABOUT NERVENTRA NERVENTRA is a once-daily oral, investigational, CNS-active immunomodulator with a novel mechanism of action being developed for the treatment of relapsing-remitting MS (RRMS) and progressive MS (PMS). In extensive non-clinical and clinical studies NERVENTRA has demonstrated both anti-inflammatory and neuroprotective properties and effects that have been shown to provide clinically meaningful results. The global Phase III clinical development program evaluating NERVENTRA in … Continue reading →

Posted in MS Treatment | Comments Off on Teva and Active Biotech Remain Committed to the Development of NERVENTRA® (laquinimod) for Multiple Sclerosis …

Teva’s Laquinimod MS Pill Fails to Win EU Agency Backing

Posted: Published on January 24th, 2014

Teva Pharmaceutical Industries Ltd. (TEVA) failed to win backing from the European Union drug regulator for a new pill to treat multiple sclerosis, hurting the companys effort to introduce a successor to its best-selling injection Copaxone. The drug, laquinimod, shouldnt be granted marketing authorization in the 28-nation EU, the European Medicines Agencys Committee for Medicinal Products for Human Use said in a statement today. The agency was concerned that animal studies showed a higher occurrence of cancers and possible risk to unborn babies, the London-based agency said. The product would have competed against oral medicines from Biogen Idec Inc. (BIIB), Novartis AG (NOVN) and Sanofi. (SAN) Laquinimod showed disappointing results in clinical trials in 2011. After talks with the Food and Drug Administration, Teva decided not to seek U.S. approval without another trial, the Petach Tikva, Israel-based company said that year. Analysts have no sales estimates for the drug, which has the brand name Nerventra, according to data compiled by Bloomberg. Active Biotech AB (ACTI) is Tevas partner on the drug. Teva and Active Biotech are focusing on evaluating the CHMPs review and will continue to liaise closely with the EMA in working to make Nerventra available as a new … Continue reading →

Posted in MS Treatment | Comments Off on Teva’s Laquinimod MS Pill Fails to Win EU Agency Backing

BioMarin’s Pipeline Encourages – Analyst Blog

Posted: Published on January 24th, 2014

BioMarin Pharmaceutical Inc. ( BMRN ) has a robust pipeline with several data readouts expected this year. The most important pipeline at BioMarin is Vimizim. The candidate is being developed for the treatment of patients suffering from mucopolysaccharidosis Type IVA (MPS IVA) or morquio A syndrome. The candidate is expected to be approved in the U.S. later in the year (target date: Feb 28, 2014) following the positive opinion of a panel of the U.S. Food and Drug Administration in Nov 2013. BioMarin is also seeking approval of the candidate in the EU. Approval of the candidate has also been sought in other countries like Canada. Other interesting candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently undergoing phase III development for the treatment of PKU. The pipeline at BioMarin also includes BMN-673 (a poly polymerase inhibitor). In Oct 2013, the company initiated a phase III study on BMN 673 in germline BRCA (gBRCA) breast cancer. Another pipeline candidate is BMN-701, which is being developed to combat Pompe's disease. Moreover, a 48 week phase I/II study (n~22) on BMN 190 for treating patients suffering from Batten disease is underway. BMN 111, for treating children suffering from achondroplasia, is … Continue reading →

Comments Off on BioMarin’s Pipeline Encourages – Analyst Blog

Restoring Health With Hormone Replacement Therapy by Dr. Howard Liebowitz – Video

Posted: Published on January 24th, 2014

Restoring Health With Hormone Replacement Therapy by Dr. Howard Liebowitz http://www.liebowitzlongevity.com - Restoring Health With Hormone Replacement Therapy by Dr. Howard Liebowitz and Randy Alvarez on the Wellness Hour. Dr. Lie... By: liebowitzlongevity … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Restoring Health With Hormone Replacement Therapy by Dr. Howard Liebowitz – Video

Update on Hormone Replacement Therapy – Video

Posted: Published on January 24th, 2014

Update on Hormone Replacement Therapy Dr. Thornton provides the most recent concensus on hormone replacement. By: Ask the Gynecologist … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Update on Hormone Replacement Therapy – Video

Hormone Therapy May Cut Risk of Repeat Joint Replacement Surgery in Women

Posted: Published on January 24th, 2014

Those who took it after hip, knee replacement saw risk of second procedure drop by about 40 percent WebMD News from HealthDay By Steven Reinberg HealthDay Reporter THURSDAY, Jan. 23, 2014 (HealthDay News) -- Women who start hormone replacement therapy after having had hip or knee replacement surgery may cut their risk of needing another procedure in the same joint by nearly 40 percent, a new study suggests. About 2 percent of those who have a hip or knee replacement need another surgery within three years. Most of these additional procedures are needed because of a complication known as osteolysis, which happens when tiny pieces of the implant seep into the tissue around the implant, causing inflammation that destroys the bone around the implant, the British researchers explained. "There is evidence that drugs like hormone replacement therapy, used usually to prevent osteoporosis and fractures, might have a beneficial effect on implant survival in patients undergoing knee or hip replacement," said lead researcher Dr. Nigel Arden, director of musculoskeletal epidemiology at the University of Oxford in England. "These findings must be confirmed in further studies, but they are consistent with previous reports by our group showing an association between use of … Continue reading →

Posted in Hormone Replacement Therapy | Comments Off on Hormone Therapy May Cut Risk of Repeat Joint Replacement Surgery in Women

Scientists find estrogen promotes blood-forming stem cell function

Posted: Published on January 24th, 2014

Jan. 22, 2014 Scientists have known for years that stem cells in male and female sexual organs are regulated differently by their respective hormones. In a surprising discovery, researchers at the Children's Medical Center Research Institute at UT Southwestern (CRI) and Baylor College of Medicine have found that stem cells in the blood-forming system -- which is similar in both sexes -- also are regulated differently by hormones, with estrogen proving to be an especially prolific promoter of stem cell self-renewal. The research, published in Nature, raises several intriguing possibilities for further investigation that might lead to improved treatments for blood cancers and increased safety and effectiveness of chemotherapy. Before the finding, blood-forming stem cells were thought to be regulated similarly in both males and females, according to the paper's senior author, Dr. Sean Morrison, Director of CRI, Professor of Pediatrics, and the Mary McDermott Cook Chair in Pediatric Genetics at UT Southwestern Medical Center. However, while working in Dr. Morrison's laboratory as postdoctoral fellows, Dr. Daisuke Nakada, the first and co-corresponding author of the study, and Dr. Hideyuki Oguro discovered that blood-forming stem cells divide more frequently in females than in males due to higher estrogen levels. The research, … Continue reading →

Posted in Stem Cell Research | Comments Off on Scientists find estrogen promotes blood-forming stem cell function

Page 4,670«..1020..4,6694,6704,6714,672..4,6804,690..»